Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine

Journal Article · · Journal of Nuclear Medicine; (USA)
OSTI ID:6983765
; ;  [1]
  1. Hahnemann University Hospital, Philadelphia, PA (USA)

Markedly altered biodistribution of ({sup 67}Ga)citrate was observed in a 66-yr-old hemodialysis patient imaged at 48 hr postinjection. A review of the patient's hospital records revealed toxic serum levels of aluminum, treated with the chelating agent desferoxamine. Based on what is known about the biologic interactions between gallium, aluminum, transferrin, and desferoxamine, we believe that both toxic serum aluminum levels and desferoxamine therapy may cause altered biodistribution on ({sup 67}Ga)citrate scintigraphy.

OSTI ID:
6983765
Journal Information:
Journal of Nuclear Medicine; (USA), Journal Name: Journal of Nuclear Medicine; (USA) Vol. 31:1; ISSN 0161-5505; ISSN JNMEA
Country of Publication:
United States
Language:
English